<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $25.80 per share for the second quarter, beating the $17.69 estimate. It clocked revenue of $5.1 billion, surpassing the analysts’ consensus of $3.89 billion and higher than $1.95 billion a year ago, primarily attributable to sales from COVID-19 treatment, REGEN-COV.
...read full article on Benzinga
